Added to YB: 2025-04-16
Pitch date: 2025-04-15
BIOA [bullish]
BioAge Labs, Inc.
+42.67%
current return
Author Info
A team of 15-year-olds who share long, short, and quant trading ideas. Sign up for the newsletter.
Company Info
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
Market Cap
$291.9M
Pitch Price
$3.75
Price Target
7.00 (+31%)
Dividend
N/A
EV/EBITDA
0.82
P/E
-2.68
EV/Sales
-8.36
Sector
Pharmaceuticals
Category
value
Long BIOA: The biotech company whose cash reserves are more than double its market cap, which also possess a prized hidden asset which makes it a ripe acquisition target
BIOA: Long at 80% discount post-obesity drug failure. $150M mkt cap w/ $330M cash ($10/share) & NLRP3 asset (CNS-penetrant inflammation drug). Novartis deal: $20M upfront, $530M milestones. NLRP3 programs fetch $100Ms from pharma giants. IND filing 2H25; Phase 1 1H26. PT $7.
Read full article (10 min)